Tissue targeting and plasma clearance of cobra venom factor in mice

被引:14
|
作者
Fu, QL
Satyaswaroop, PG
Gowda, DC
机构
[1] GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20007
[2] PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT OBSTET & GYNECOL,HERSHEY,PA 17033
关键词
D O I
10.1006/bbrc.1997.6078
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The tissue targeting and rate of clearance of cobra venom factor (CVF) from the circulation was studied in mice by intravenous or intraperitoneal injection of radioiodinated CVF. In both modes of administrations, CVF was targeted mainly to liver. CVF injected directly into the blood was cleared from the circulation with a plasma half life of about 10 h, whereas CVF injected into the peritoneal cavity was slowly absorbed into the blood stream reaching a maximum level at similar to 6 h, and it was then cleared from the circulation with a plasma half life of about 18 h. The rate of plasma clearance of CVF was markedly decreased upon removal of the terminal alpha-galactosyl residues of the oligosaccharide chains; the plasma half lives for intravenously and intraperitoneally administered de-alpha-galactosylated CVF were similar to 5 and similar to 10 h, respectively. However, the clearance rate was not affected by complete deglycosylation using N-glycanase or by chemical modification of the terminal galactosyl residues. Together, these data demonstrate that the terminal alpha-galactosyl residues of CVF mask the Lewis X-dependent uptake of CVF by liver. (C) 1997 Academic Press.
引用
收藏
页码:316 / 320
页数:5
相关论文
共 50 条
  • [1] Treatment with Cobra Venom Factor Decreases Ischemic Tissue Damage in Mice
    Azubuike-Osu, Sharon O.
    Kuhs, Amelie
    Goetz, Philipp
    Faro, Anna
    Preissner, Klaus T.
    Arnholdt, Christoph
    Deindl, Elisabeth
    BIOMEDICINES, 2024, 12 (02)
  • [2] Cobra Venom Factor Boosts Arteriogenesis in Mice
    Goetz, Philipp
    Azubuike-Osu, Sharon O.
    Braumandl, Anna
    Arnholdt, Christoph
    Kuebler, Matthias
    Richter, Lisa
    Lasch, Manuel
    Bobrowski, Lisa
    Preissner, Klaus T.
    Deindl, Elisabeth
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
  • [3] Pharmacokinetics of humanized cobra venom factor in mice
    Fritzinger, David C.
    Damaj, Bassam B.
    Wong, Katina
    Vogel, Carl-Wilhelm
    Finnegan, Paul W.
    MOLECULAR IMMUNOLOGY, 2010, 47 (13) : 2268 - 2269
  • [4] COBRA VENOM FACTOR
    VOGEL, CW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 209 : 29 - AGFD
  • [5] Generation and characterization of transgenic mice expressing cobra venom factor
    Andrä, J
    Halter, R
    Kock, MA
    Niemann, H
    Vogel, CW
    Paul, D
    MOLECULAR IMMUNOLOGY, 2002, 39 (5-6) : 357 - 365
  • [6] MODULATION OF DELAYED-HYPERSENSITIVITY IN MICE BY COBRA VENOM FACTOR
    BLOKSMA, N
    VANDIJK, H
    BIJLSMA, W
    WILLERS, J
    CELLULAR IMMUNOLOGY, 1979, 46 (01) : 187 - 191
  • [7] Recombinant cobra venom factor
    Vogel, CW
    Fritzinger, DC
    Hew, BE
    Thorne, M
    Bammert, H
    MOLECULAR IMMUNOLOGY, 2004, 41 (2-3) : 191 - 199
  • [8] Absence of a neutralizing antibody response to humanized cobra venom factor in mice
    Ing, Mathieu
    Hew, Brian E.
    Fritzinger, David C.
    Delignat, Sandrine
    Lacroix-Desmazes, Sebastien
    Vogel, Carl-Wilhelm
    Rayes, Julie
    MOLECULAR IMMUNOLOGY, 2018, 97 : 1 - 7
  • [9] Cobra Venom Factor and Ketoprofen Abolish the Antitumor Effect of Nerve Growth Factor from Cobra Venom
    Osipov, Alexey V.
    Terpinskaya, Tatiana I.
    Kuznetsova, Tatiana E.
    Ryzhkovskaya, Elena L.
    Lukashevich, Vladimir S.
    Rudnichenko, Julia A.
    Ulashchyk, Vladimir S.
    Starkov, Vladislav G.
    Utkin, Yuri N.
    TOXINS, 2017, 9 (09)
  • [10] Structure and function of cobra venom factor, the complement-activating protein in cobra venom
    Vogel, CW
    Bredehorst, R
    Fritzinger, DC
    Grunwald, T
    Ziegelmuller, P
    Kock, MA
    NATURAL TOXINS 2: STRUCTURE, MECHANISM OF ACTION, AND DETECTION, 1996, 391 : 97 - 114